Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02879578 · ClinicalTrials.gov registry record · Phase 2
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
A Phase 2 study, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT02879578 is a Phase 2 study that has completed, run by Neurocrine Biosciences. The registered enrollment target is 155 participants.
The verdict
NCT02879578, a Phase 2 study, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).
Interventions
- DRUG Valbenazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2016-07-25 |
| Est. Completion | 2017-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02879578
The ClinicalTrials.gov registry entry for NCT02879578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valbenazine is the first listed.
NCT02879578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02879578 about?
NCT02879578 is a clinical study titled "Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome". Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).
What is the current status of trial NCT02879578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2016-07-25. Estimated completion is 2017-11-01.
What interventions are being tested in trial NCT02879578?
The interventions under investigation include: Valbenazine (DRUG).
Who is sponsoring clinical trial NCT02879578?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.